Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: daveG who wrote (761)	1/21/1999 1:33:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1255

No. A large company can take a set of molecules into its own labs for pharmacokinetic and animal studies prior to inking a final deal, and probably Organon did that. But that is with Cortex's permission. It is possible that other companies have done so, but I know that Cortex and Organon have been dancing for a long time, and Organon may have been the only company that went into the ultimate stage of due diligence review. No company is going to run human studies on a drug they have not in-licensed. NeuroInvestment (www.neuroinvestment.com)